Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / [The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients].

< BACK TO ARCHIVE


2020 Jul-Sep


Rev Alerg Mex


http://www.ncbi.nlm.nih.gov/pubmed/33636066?dopt=Abstract


67


3

[The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients].

Authors

[The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients].
Hernández-Morales M R, Mancilla-Hernández E
Rev Alerg Mex. 2020 Jul-Sep; 67(3):237-244.
PMID: 33636066.

Abstract

Trimethoprim with sulfamethoxazole (TMP-SMX) is the drug of choice for the prophylaxis of AIDS-associated comorbidities.
Read This Paper